

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC, 20231, ON THE DATE APPEARING BELOW.

AHP-9897-6-N5  
PATENT



DATE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: R. E. Morris  
C. R. Gregory

Serial No.: 08/452,051

Examiner:

Filed: May 26, 1995

Group: 1808

For: Method of Treating Hyperproliferative  
Vascular Disease

Assistant Commissioner for Patents  
Washington, DC 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.97(b)(1)**


Sir:

Transmitted herewith is an Information Disclosure Statement for the above identified application that is being mailed within three months of the filing date of May 26, 1995. No fee is due.

The Commissioner is hereby authorized to charge any additional fee due as required under 37 C.F.R. 1.17(p) by this paper to Deposit Account No. 01-1425. Two additional copies of this sheet are enclosed.

Respectfully submitted,

Dated: August 17, 1995  
Telephone: (610) 902-2635

  
Arnold S. Milowsky  
Reg. No. 35,288

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC, 20231, ON THE DATE APPEARING BELOW.

1808  
AHP-9897-6-N5  
PATENT



DATE

*August 17, 1995*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: R.E. Morris  
C.R. Gregory

Serial No.: 08/452,051

Examiner:

Filed: May 26, 1995

Group: 1808

For: Method of Treating Hyperproliferative Vascular Disease

Assistant Commissioner for Patents  
Washington, DC 20231

*#5 08/21/95 1-0096*

**INFORMATION DISCLOSURE STATEMENT UNDER RULE 97(b)(1)**

Sir:

With respect to the subject matter of the above-identified application, the applicant is aware of the following references, which may have relevance to the examination of the invention claimed. These references were cited by the applicants or cited by the Examiner in U.S.S.N. 08/238,305 U.S.S.N. 07/980,000, or U.S.S.N. 07/819,314 from which priority under 35 U.S.C. 120 are claimed. Copies of these references are not enclosed pursuant to 37 C.F.R. 1.98(d).

American Society of Transplant Physicians, 13th Annual Meeting, May 16-18, 1994;

Abstract (38) 9, mailed to attendees April 27, 1994

American Society of Transplant Physicians, 13th Annual Meeting, May 16-18, 1994;

Abstract (38) 10, mailed to attendees April 27, 1994

Transplantation Proc. 25: 120 (1993)

Transplantation Proc. 25: 770 (1993)

Transplantation 55: 1409 (1993)

Veterinary Surgery, 11 Abstract 40 (1993)

J. Heart Lung Transplant 11: 197 (Abs 27) (1992)

FASEB 6: A940 (Abs 21) (1992)

U.S. Patent 5,100,899


J. Heart Lung Transplant. 9: 55 (1990)

Lancet 338: 1297 (1991)

Circulation 80 (Supp. II): 183 (1989)

Proc. Natl. Acad. Sci. 85: 2303 (1988)  
U.S. Patent 3,929,992  
Transplantation Reviews 6: 39 (1992)  
FASEB 3,3411 (1989)  
Can. J. Physiol. Pharmacol. 55, 48 (1977)  
Med. Sci. Res. 17: 877 (1989)  
European Patent Application 0401747 A2  
U.S. Patent 5,078,999  
U.S. Patent 5,080,899  
Abstract: Fifth Int. Conf. of Inflammation Research Association 121, September 23, 1990  
J. Antibiotics 37: 1231 (1984)  
U.S. Patent Application S.N. 07/717,773 (filed 6/18/91)  
U.S. Patent 4,885,171  
The Merck Index, Ed. pp. 820-821, No. 6152 (1976)  
J. Cell Biol 111: Abstract 1308, p. 234a  
Transplantation Proc. 23: 2833 (1991)  
Cytokine 3: 472 (1991)  
Transplantation Proc. 23: 507 (1991)  
Transplantation 50: 554 (1990)  
Immunology 72: 544 (1991)  
Ferns, G., Am. J. Path. 137: 403 (1990)  
U.S. Patent 5,288,711  
U.S. Patent 5,256,790  
U.S. Patent 5,252,579

Respectfully submitted,

  
\_\_\_\_\_  
Arnold S. Milowsky  
Reg. No. 35,288

Dated: August 17, 1995  
Telephone: (610) 902-2635